MEDIVATION INC (MDVN)
(Delayed Data from NSDQ)
$81.44 USD
+0.02 (0.03%)
Updated Sep 27, 2016 04:14 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[MDVN]
Reports for Purchase
Showing records 1 - 20 ( 252 total )
Industry: Medical - Biomedical and Genetics
Recent Drug Launch Weekly Retail Sales Tracker
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Recent Drug Launch Weekly Retail Sales Tracker- Week Ended Sept. 9
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharmaceuticals - Recent Drug Launch Weekly Retail Sales Tracker- Week Ended Aug 26
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Downgrading to NEUTRAL; Pfizer to Buy MDVN for ~$14B, Raising PT to $81.50
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Biopharmaceuticals - Recent Drug Launch Weekly Retail Sales Tracker- Week Ended Aug 12
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Q2 EPS; Reaffirming Financial Guidance Ahead of TERRAIN PDUFA; Reiterate OUTPERFORM and $66 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Astellas Reports 2Q Xtandi Sales In-Line with Expectations, Reiterate OP
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Recent Drug Launch Weekly Retail Sales Tracker- Week Ended July 22
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
2Q Preview; Xtandi Script Growth Trends and Other Developments, Raising PT to $66 and Reiterating O
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
We believe Medivation continues to be a buyout target.
Provider: G.RESEARCH, LLC
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Recent Drug Launch Weekly Retail Sales Tracker- Week Ended June 24
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Recent Drug Launch Weekly Retail Sales Tracker- Week Ended June 17
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Recent Drug Launch Weekly Retail Sales Tracker - Week Ended May 20
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Industry: Medical - Biomedical and Genetics
Recent Drug Launch Weekly Retail Sales Tracker - Week Ended May 13
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D